The estimated Net Worth of David V Goeddel is at least $1.7 Milione dollars as of 15 November 2023. David Goeddel owns over 26,811 units of Ngm Biopharmaceuticals Inc stock worth over $1,462,787 and over the last 5 years he sold NGM stock worth over $0. In addition, he makes $240,368 as Lead independent director at Ngm Biopharmaceuticals Inc.
Sign up
David Goeddel NGM stock SEC Form 4 insiders trading
David has made over 39 trades of the Ngm Biopharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 26,811 units of NGM stock worth $18,231 on 15 November 2023.
The largest trade he's ever made was buying 984,161 units of Ngm Biopharmaceuticals Inc stock on 9 June 2022 worth over $13,286,174. On average, David trades about 136,130 units every 34 days since 2019. As of 15 November 2023 he still owns at least 949,862 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of David Goeddel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Goeddel biography
Dr. David V.N. Goeddel Ph.D. serves as Lead independent director of the Company. Dr. Goeddel became Lead Independent Director of our Board of Directors in September 2018, after having served as Chairman since January 2008, and served as our Chief Executive Officer from 2008 to 2010. Dr. Goeddel has been a Managing Partner of The Column Group (“TCG”), a venture capital partnership, since 2007. Dr. Goeddel co-founded Tularik in November 1991, was Vice President of Research until 1996 and Chief Executive Officer from 1996 through 2004. He served as Amgen’s first Senior Scientific Vice President until May 2006. Prior to Tularik, he was the first scientist hired by Genentech, and from 1978 to 1993 served in various positions, including Fellow, Staff Scientist and Director of Molecular Biology. Dr. Goeddel has served as a director at RAPT Therapeutics, Inc., a publicly-traded biotechnology company, since 2015. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Dr. Goeddel received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. from the University of Colorado.
What is the salary of David Goeddel?
As the Lead independent director of Ngm Biopharmaceuticals Inc, the total compensation of David Goeddel at Ngm Biopharmaceuticals Inc is $240,368. There are 9 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of $2,092,150.
How old is David Goeddel?
David Goeddel is 68, he's been the Lead independent director of Ngm Biopharmaceuticals Inc since 2018. There are no older and 17 younger executives at Ngm Biopharmaceuticals Inc.
What's David Goeddel's mailing address?
David's mailing address filed with the SEC is 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO, CA, 94129.
Insiders trading at Ngm Biopharmaceuticals Inc
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel e Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
What does Ngm Biopharmaceuticals Inc do?
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
What does Ngm Biopharmaceuticals Inc's logo look like?
Complete history of David Goeddel stock trades at Ngm Biopharmaceuticals Inc e RAPT Therapeutics
Ngm Biopharmaceuticals Inc executives and stock owners
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
David Woodhouse,
Chief Executive Officer, Director -
Jin-Long Chen,
Founder, Chief Scientific Officer, Director -
William Rieflin,
Executive Chairman of the Board of Directors -
Suzanne Hooper,
Independent Director -
Dr. David J. Woodhouse Ph.D.,
CEO & Director -
Dr. Jin-Long Chen Ph.D.,
Founder, Chief Scientific Officer & Director -
Shelly Guyer,
Independent Director -
Siobhan Nolan Mangini,
CFO and Principal Financial & Accounting Officer -
McHenry Tichenor,
Independent Director -
David Goeddel,
Lead independent director -
David Schnell,
Independent Director -
Mark Leschly,
Independent Director -
William J. Rieflin J.D.,
Exec. Chairman of Directors -
Siobhan Mangini,
Chief Financial Officer -
Carole Ho,
Independent Director -
Hsiao Lieu,
Senior Vice President, Chief Medical Officer -
Marc Learned,
Vice President - Research Operations -
Hui Tian,
Senior Vice President - Research -
Wenyan Shen,
Senior Vice President - Biologics and CMC -
Alex DePaoli,
Senior Vice President, Chief Translational Officer -
Valerie Pierce,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Dr. Hsiao Dee Lieu,
Chief Medical Officer & Sr. VP -
Brian Muma,
VP of HR -
Valerie L. Pierce J.D.,
Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Alexander Duke Schwartz,
Exec. Director of Investor Relations -
Group L Ptcg Opportunity Ii...,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Gp, L...,
-
Group L P Svennilson Peter ...,
-
Peter Svennilson,
Director -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Iii, ...,
-
Aetna Wun Trombley,
President & COO -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Ii, L...,
-
Group L P Ponoi Capital Ii,...,
-
Group L Pcolumn Group Iii, ...,
-
Roger M Perlmutter,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Iii, ...,
-
Jean Frederic Viret,
Chief Financial Officer -
Group Gp, Lpcolumn Group Ii...,
-
Opportunity Iii Gp, Llc Tcg,
10% owner -
Irene Perlich,
Principal Accounting Officer